{"id":"W7108659049","doi":"10.1182/blood-2025-2118","title":"A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Obinutuzumab; Venetoclax; Fludarabine; Chemoimmunotherapy; Post-hoc analysis; Discontinuation; Adverse effect; Cyclophosphamide; Neutropenia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008004306,0.0001641996,0.0005472064,0.00027894,0.0001665086,0.00003974003,0.0003020946,0.0001838317,0.0002270894],"category_scores_gemma":[0.001489587,0.000119066,0.0002909993,0.00168882,0.0001690967,0.00005637696,0.00008492104,0.0002817661,0.00001444486],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001931498,"about_ca_system_score_gemma":0.005445373,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002775362,"about_ca_topic_score_gemma":0.0003016674,"domain_scores_codex":[0.9978164,0.0001841452,0.000842296,0.0003647784,0.0005354654,0.0002568743],"domain_scores_gemma":[0.9967685,0.001584103,0.0002339629,0.001003354,0.0003425655,0.00006752167],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7653542,0.02282384,0.0007393165,0.0002224747,0.04295029,0.000109112,0.008530967,0.0002951128,0.09791398,0.006900013,0.01003925,0.04412149],"study_design_scores_gemma":[0.9407963,0.001300628,0.006698505,0.0001549156,0.0059422,0.00000501482,0.0003367681,0.01325658,0.0200181,0.0001496231,0.01116439,0.0001770138],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911534,0.0004698369,0.0002432004,0.003472515,0.0001308078,0.001246344,0.001147144,0.00005157937,0.002085173],"genre_scores_gemma":[0.9951196,0.0002202601,0.0002043977,0.0005147255,0.0001293964,0.0000619381,0.00249106,0.00001621939,0.001242379],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1754421,"threshold_uncertainty_score":0.9659858,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01878133108254036,"score_gpt":0.3385754346485994,"score_spread":0.319794103566059,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}